Randomized, Placebo-Controlled, Dose-Escalating, Double-Blinded Phase 1 Safety and Immunogenicity Study of Clade C DNA Vaccine ADVAX e/g + ADVAX p/N-t (ADVAX) Administered Intramuscularly to HIV-Uninfected, Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 04 Oct 2018
At a glance
- Drugs ADVAX (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacodynamics
- Acronyms C001
- 12 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Nov 2005 New trial record.